CC
UTHR icon

Centiva Capital’s United Therapeutics UTHR Stock Holding History

Centiva Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,656
Closed -$846K – 2621
2024
Q2 		$846K Buy
+2,656
New +$703K 0.01% 860
2024
Q1 		– Sell
-1,069
Closed -$235K – 2288
2023
Q4 		$235K Sell
1,069
-181
-14% -$41.7K 0.01% 1334
2023
Q3 		$282K Buy
+1,250
New +$288K 0.01% 1209
2021
Q4 		– Sell
-1,748
Closed -$320K – 1564
2021
Q3 		$320K Sell
1,748
-1,075
-38% -$212K 0.02% 763
2021
Q2 		$506K Buy
2,823
+1,616
+134% +$308K 0.01% 825
2021
Q1 		$202K Buy
+1,207
New +$201K 0.01% 966
2020
Q1 		– Sell
-3,530
Closed -$311K – 922
2019
Q4 		$311K Buy
+3,530
New +$311K 0.02% 555

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Centiva Capital's UTHR Position: Q3 2024 in Review

Centiva Capital sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 2,656 shares — an estimated $846K sold.

Centiva Capital first reported a position in UTHR in Q4 2019 and held it in 7 quarters. The position peaked at $846K in Q2 2024. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • Centiva Capital reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 2,656 United Therapeutics shares in Q3 2024, an estimated $846K.
  • Centiva Capital first reported a position in United Therapeutics in Q4 2019 and held it in 7 quarters.
  • Centiva Capital's United Therapeutics position peaked at $846K in Q2 2024.
  • 625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.